

1. Gabutti V, Piga A. Results of Long-Term Iron-Chelating Therapy. *Acta Haematol* 1996; 95:26–36.
2. Wolfe L C, Olivieri N F, Sallan D, Colan S, Rose V, Propper R D et al. Prevention of cardiac disease by subcutaneous desferrioxamine in patients with thalassemia major. *N Engl J Med* 1985; 312(25): 1600–1603.
3. Aldouri M A, Wonke B, Hoffbrand A V, Flynn D M, Ward S E, Agnew J E et al. High Incidence of Cardiomyopathy in Beta-Thalassemia Patients Receiving Regular Transfusion and Iron Chelation: Reversal by Intensified Chelation. *Acta Haematol* 1990; 84:113–117.
4. Brittenham G M, Griffith P M, Noruis A W, McLaren C E, Young N S, Tucker E E et al. Efficacy of Desferrioxamine in Preventing Complications of Iron Overload in Patients with Thalassemia Major. *N Engl J Med* 1994; 331(9):567–573.
5. Giardina P J V, Ehlers K H, Engle M A, Grady R W, Hilgartner M W. The Effect of Subcutaneous Desferrioxamine on the Cardiac Profile of Thalassemia Major: A Five-Year Study. *Ann N Y Acad Sci* 1985; 445:282–292.
6. Borgna-Pignatti C, Rugolotto S, DeStefano P, Piga A, et al. Survival and Disease Complications in Thalassemia Major. *Ann N Y Acad Sci* 1998; 850:227–231.
7. Olivieri N F, Nathan D G, MacMillan J H, Wayne A S, Liu P, McGee A et al. Survival in Medically Treated Patients with Homozygous Beta-Thalassemia. *N Engl J Med* 1994; 331(9):574–578.
8. Addis A, Loebstein R, Koren G, Einarsen T R. Meta-analytic review of the clinical effectiveness of oral deferiprone (Deferiprone). *Eur J Clin Pharmacol* 1999; 55:1–6.
9. Grady R W, Hilgartner M W, Giardina P J V. Deferiprone: Its Effectiveness Relative to that of Desferrioxamine. 6th International Conference on Thalassemia and the Haemoglobinopathies, Abstract #2. 1997.
10. Olivieri N F, Brittenham G M, Armstrong S A M, Basran R K, Daneman R, Daneman N et al. First Prospective Randomized Trial of the Iron Chelators Deferiprone (Deferiprone) and Deferoxamine. *Blood* 86[10 Suppl. 1], 249a. 1995.
11. Olivieri N F, Belluzzo N, Muraca M, MacKenzie C C, Milone S, Polsinelli K et al. Evidence of Reduction in Hepatic, Cardiac and Pituitary Iron Stores in Patients with Thalassemia Major During Long-Term Therapy with the Orally Active Iron Chelating Agent Deferiprone. *Blood* 84[10 Suppl. 1]109a. 1994.
12. Link G, Konijn A M, Hershko C. Cardioprotective effect of alpha-tocopherol, ascorbate, desferrioxamine, and deferiprone: mitochondrial function in cultured, iron-loaded heart cells. *J Lab Clin Med* 1999; 133: 179–188.
13. De Franceschi L, Shalev O, Piga A, Collell M, Olivieri O, Corrocher R et al. Deferiprone therapy in homozygous human beta-thalassemia removes erythrocyte membrane free iron and reduces KCl contransport activity. *J Lab Clin Med* 1999; 133:64–69.
14. Carthew P, Smith A G, Hider R C, Dorman B, Edwards R E, Francis J E. Potentiation of iron accumulation in cardiac myocytes during the treatment of iron overload in gerbils with the hydroxypridinone iron chelator CP94. *Biometals* 1994; 7:267–271.
15. Hider R C, Kayyali R, Evans P, Mackinnon S. The production of Hydroxyl Radicals by Deferiprone-iron compounds under physiological conditions. *Blood* 94[10], 406a. 1999.
16. Engle M A, Erlandson M, Smith C H. Late Cardiac Complications of Chronic, Severe, Refractory Anemia with Hemochromatosis. *Circulation* 1964; 30:698–705.
17. The Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of Disease of the heart and Great Vessels. 9th ed. Boston, Mass; Little, Brown & Co; 1994:253–255.
18. Sirchia G, Zanella A. A Short Guide to the Management of Thalassemia. *Thalassemia Today: the Mediterranean Experience*. 1987: 635–670.
19. Berdoukas V, Bohans T. The Effect of Liver Iron on Cardiac Function. 10th International Conference on Oral Chelators in the treatment of Thalassemia and other diseases and Biomed Meeting 10, 13. 2000.
20. Hershko C, Graham G, Bates G W, Rachmilewitz E A. Non-Specific Serum iron in Thalassemia: an Abnormal Serum Iron Fraction of Potential Toxicity. *Br J Haematol* 1978; 40: 255–263.
21. Olivieri N F, Koren G, Matsui D, Liu P, Blendis L, Cameron R et al. Reduction of Tissue Iron Stores and Normalization of Serum Ferritin During Treatment with the Oral Iron Chelator Deferiprone in Thalassemia Intermedia. *Blood* 1992; 79(10):2741–2748.
22. Al-Refaie F N, Sheppard L, Nortey P, Wonke B, Hoffbrand A V. Pharmacokinetics of the Oral Iron Chelator Deferiprone (Deferiprone) in Patients with Iron Overload. *Br J Haematol* 1995; 89:403–408.
23. Novartis Marketing Brochure on Desferal (Desferrioxamine). 1998. Switzerland, Novartis Pharma AG.
24. Grady R W, Berdoukas V A, Rachmilewitz E A, Giardina P J. Combining Deferiprone and Desferrioxamine to optimize Chelation. 10th International Conference on Oral Chelators in the treatment of Thalassemia and other diseases and Biomed Meeting, Limassol, Cyprus Page 9. March 2000.
25. Töndury P, Zimmermann A, Nielsen P, Hirt A. Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassaemic patients. *Br. J. Haematol.* 1998;101(3):413–5.
26. Olivieri N F, Brittenham G M, McLaren C E, Templeton D M, Cameron R G, McClelland R A et al. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. *N Engl J Med* 1998; 339(7):417–423.
27. Hoffbrand A V, Al-Refaie F N, Davis B, Siritanakatkul N, Jackson B F A, Cochrane J et al. Long-Term Trial of Deferiprone in 51 Transfusion-Dependent Iron Overloaded Patients. *Blood* 1998; 91(1):295–300.
28. Olivieri N F, Butany J, Templeton D M, Brittenham G M. Cardiac Failure and Myocardial Fibrosis in a patient with Thalassemia Major (TM) Treated with Long-Term Deferiprone. *Blood* 92[10 (Suppl 1)], 532a. 1998.
29. Cohen A R, Galanello R, Piga A, DiPalma A, Vullo C, Tricta F. Safety profile of the oral iron chelator deferiprone: a multicentre study. *Br J Haematol* 2000; 108: 305–312.
30. Agarwal MB, Rajadhyaksha G, Munot S. Deferiprone: A report of 22 patients who have taken it for over a decade. 10th International Conference on Oral chelators in the Treatment of Thalassemia and other Diseases and Biomed Meeting, Limsol, Cyprus, Page 3. March 2000.
31. Liu P. Personal letter from Dr. Liu on reversal of the heart failure in a patient with thalassemia treated with deferiprone. May 13, 1996.